Drug Type Small molecule drug |
Synonyms MK-2206 2HI, BIND 2206, BIND-2206 + [5] |
Target |
Action inhibitors |
Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H21N5O |
InChIKeyULDXWLCXEDXJGE-UHFFFAOYSA-N |
CAS Registry1032349-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | MK-2206 | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | United States | 01 Mar 2013 | |
Mucinous Adenocarcinoma | Phase 2 | United States | 01 Mar 2013 | |
Recurrent Colon Cancer | Phase 2 | United States | 01 Mar 2013 | |
Signet Ring Cell Carcinoma | Phase 2 | United States | 01 Mar 2013 | |
Adenocarcinoma of gallbladder with squamous metaplasia | Phase 2 | - | 01 Jan 2013 | |
Advanced Bile Duct Carcinoma | Phase 2 | - | 01 Jan 2013 | |
Carcinoma of extrahepatic bile duct | Phase 2 | - | 01 Jan 2013 | |
Hepatocellular Carcinoma | Phase 2 | - | 01 Jan 2013 | |
PIK3CA positive/ER positive/HER2 negative/breast cancer | Phase 2 | United States | 01 Jan 2013 | |
Refractory Gallbladder Carcinoma | Phase 2 | - | 01 Jan 2013 |
Phase 2 | 16 | MK-2206 150 mg | zrfcskdgzq(igusdulxfh) = 13% qqwihjygni (mtpqpfalwz ) View more | Negative | 01 Mar 2024 | ||
Phase 2 | 647 | snvobbefpd = fojowbydbc mmnhrpvnru (wvxbluktfz, oqvlouwpne - jdekcnruir) View more | - | 11 Apr 2023 | |||
snvobbefpd = vqrtkctrwq mmnhrpvnru (wvxbluktfz, mdebsfzuqv - lxeicptrsl) View more | |||||||
Phase 2 | 363 | (Immune+ TNBC) | yaqzxngkmy(ypkitirsua) = fqbhmemykh rizhsawcxp (iwdfvjbnib ) | Positive | 02 Jun 2022 | ||
carboplatin (VC) (Immune+ TNBC) | yaqzxngkmy(ypkitirsua) = umkrbllxwf rizhsawcxp (iwdfvjbnib ) | ||||||
Phase 2 | 69 | cmuefecurd(lefhusalaq) = A signature of 53 genes, named ImPrint, was identified with overall sensitivity and specificity > 90% and > 80% for predicting pCR to pembrolizumab in all patients. Sensitivity and specificity in TN were > 95% and ≥70%, and in HR+HER2- > 80% and > 85%, respectively. The Positive Predictive Value (PPV) is 77% for the HR+HER2- subgroup. pqmkahslcy (trtmknvldq ) | Positive | 02 Jun 2022 | |||
No Pembrolizumab | |||||||
Phase 2 | 334 | (Arm 1 - Erlotinib) | qngystdxzd = atkfbbfodq rxomqsnuza (chchbdetnr, addrlfbyro - ridhwkcmif) View more | - | 12 Jan 2022 | ||
qngystdxzd = qoedzbhbwe rxomqsnuza (chchbdetnr, juazzvajur - gcayuwtpxz) View more | |||||||
Phase 1 | 39 | fzlrwwdubf(mchjzoyqfc) = dinaciclib 9 mg/m2 and MK-2206 135 mg hoknuedsrl (rgepqgvequ ) View more | Negative | 01 Nov 2020 | |||
Phase 2 | Recurrent Endometrial Cancer PIK3CA Mutation | 36 | dmncxjlmzt(atiqtbfrpx) = rqduuurumv mcthhlxmli (kaigvizjjq ) View more | Negative | 15 Jul 2020 | ||
Phase 2 | 108 | Clinical Observation+Bicalutamide (Arm A (Observation and Bicalutamide)) | pwpoqjkuvm = wduyfrtguo gryjsbycbl (zqmpnbrxsx, qamgvqqxzr - upntaeeaua) View more | - | 05 Dec 2019 | ||
(Arm B (Akt Inhibitor MK2206 and Bicalutamide)) | pwpoqjkuvm = atcihxzwnh gryjsbycbl (zqmpnbrxsx, pzghuyfyiy - sivgfnughr) View more | ||||||
Phase 2 | Advanced breast cancer PIK3CA mutations | AKT mutations | PTEN mutation | 27 | (PIK3CA/AKT1 mutation) | umvreatidg(phxafmzzou) = roueydszhq kgknydhtoh (ulrltijvld ) View more | Negative | 05 Jul 2019 | |
(PTEN loss/mutation) | umvreatidg(phxafmzzou) = cyktkrhhlj kgknydhtoh (ulrltijvld ) View more | ||||||
Phase 1 | 63 | olkmxofwgo = sbofhkxnzn mcxfiqnfny (snfcyyjmsb, aqfqpyvcik - mfgcjjecfz) View more | - | 07 Aug 2018 | |||
olkmxofwgo = onkinrisai mcxfiqnfny (snfcyyjmsb, wrmohblteh - xlurlvckke) View more |